



03/00002
Rec'd PCT/PTO 14 JUL 2004



LÝÐVELDIÐ ÍSLAND

*Þetta staðfestist að meðfylgjandi eru rétt afrit af gögnum sem upphaflega voru
lögð til hjá Einkaleyfastofnunni vegna neðargreindrar einkaleyfisumsóknar.*

This is to certify that the annexed is a true copy of the documents as originally
filed with the Icelandic Patent Office in connection with the following
patent application.

(21) *Umsóknarnúmer*
Patent application number

6233

(71) *Umsækjandi*
Applicant(s)

Delta hf.

(22) *Umsóknardags.*
Date of filing

15.1.2002

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

E/S
EINKALEYFASTOFNAN

Reykjavík, 14. janúar 2003

Sigurlin Bjarney Gísladóttir

Sigurlin Bjarney Gísladóttir
Patent Division

Formulations of Quinapril and related ACE inhibitors

FIELD OF THE INVENTION

- 5 The present invention is within the field of pharmaceutical formulations of ACE (Angiotensin Converting Enzyme) inhibitors, specifically formulations of quinapril and structurally related compounds.

10 TECHNICAL BACKGROUND AND PRIOR ART

- Many of the compounds useful as ACE (Angiotensin Converting Enzyme) inhibitors such as as quinapril and structurally related compounds, are prone to degradation. Specifically, such compounds can degrade via (i) cyclization via internal nucleophilic
15 reaction to form substituted diketopiperazines, (ii) hydrolysis of the side-chain ester group, and (iii) oxidation to form products having often unwanted coloration.

- Certain stabilizing compositions and formulations of such compounds have been suggested and utilized in the prior art.

20

EP 317878 suggests coating an active compound of this type with a polymeric protective coating, or mixing the compound with a physiologically tolerated buffer which ensures that a pH in the weakly acid to weakly alkaline range is set up in a pharmaceutical formulation in the presence of moisture, or both.

25

The Dictionnaire Vidal (1985) Cahier Complémentaire (p. 10, left col.) describes an enalapril maleate drug named RENITEC which as excipients contains lactose and sodium hydrogen carbonate.

- 30 EP 280999B1 suggests similar compositions using alkali or alkaline earth metal carbonates and saccharides as stabilizers for these compounds.

- However, said compounds have varied sensitivity and specific formulations need to be tested and optimized for different compounds. Consequently, alternative solutions
35 providing stable formulations will be appreciated.

It has now been surprisingly discovered that useful, stable formulations can be produced with use of basic compounds as stabilizers, preferably alkali or alkaline-earth metal carbonates, and that a saccharide compound is not needed in such formulations. An insoluble alkaline-earth metal hydrogen phosphate is further used as a preferred filler substance.

The pH of the formulations of the present invention is dominated by the basic stabilizer.


Tablets of such formulations have good storage stability, dissolution characteristics, and the formulations are suitable for use in drug combinations.

In one embodiment, 45% of magnesium carbonate is mixed with 3.9% quinapril hydrochloride with the addition of 33% calcium hydrogen phosphate (CaHPO_4).

Additional specific embodiments and experimental stability test results are disclosed in the Detailed description below and enclosed Examples.

DETAILED DESCRIPTION

The pharmaceutical formulation of the present invention comprises 0.5 – 50 wt%, such as about 1-25 wt%, including about 1-15 wt% of a compound of formula I:



wherein R^1 is hydrogen or alkyl having one to five carbon atoms; R^2 is hydrogen or C_1 - C_4 alkyl or the group

$(\text{H}_2\text{C})_n \text{---} \text{N} \begin{matrix} \text{A} \\ \text{B} \end{matrix}$ in which A and B independently denote hydrogen or C_1 - C_4 alkyl and n is 1-4; R^3 and R^4 together with the atoms they are connected to form a heterocyclic,

mono-, di-, or tricyclic ring system which is optionally substituted with C_1 - C_4 alkoxy; R^5 is methyl or phenyl; or any pharmaceutically acceptable salt thereof;

5 5 – 90 wt% of an alkali or alkaline earth metal carbonate, such as in the range of about 10 – 90 wt% and preferably in the range of about 25 – 75 wt%, such as about 25 – 50 wt%;

5 – 90 wt% including the range of about 15 – 50 wt% of an alkali or alkaline earth metal salt of hydrogen phosphate which is preferably an insoluble alkaline-earth metal salt of hydrogen phosphate, such as in the range of about 15 – 25 wt%, or in the range of 25 – 50 wt%;

10 with the proviso that the formulation does not contain a substantial amount of a saccharide compound.

15 In this context a substantial amount of a saccharide compound is meant to include any amount that would generally be considered to have a stabilizing effect on the active compound, such as more than about 10 wt%, and more preferably including an amount which is more than about 5 wt%, or even more preferably including any amount of a saccharide compound which is more than about 2 wt%.

20 The alkaline earth metal carbonate may suitably be selected from magnesium carbonate, sodium hydrogen carbonate and sodium carbonate.

25 In preferred embodiments, the amount of the alkaline earth metal carbonate is at least the equivalent of the amount of the active compound of formula I, such as e.g. at least about twice the equivalent, or at least about three times the equivalent of the amount of the active compound.

30 The term equivalent in this context refers to the conventional ionic equivalent term, one equivalent of a substance participating in a neutralization reaction is that amount of a substance that either contributes or consumes 1 mol of hydrogen ions in that reaction. I.e. for a monoacidic compound such as ramipril and a monobasic alkaline compound such as $NaHCO_3$, the equivalent ratio of the compounds is the same as the molar ratio; for a diacidic compound such as quinapril HCl stabilized with $NaHCO_3$, one equivalent of $NaHCO_3$ equals two moles of $NaHCO_3$; and likewise for a diacidic compound and dibasic alkaline compound such as Na_2CO_3 , the equivalent ratio is again the same as the molar ratio. (See, e.g. Skoog, West, Holler
35 *Fundamentals of Analytical Chemistry* 5th Ed., Saunders College Publishing, NY, 1988).

As mentioned, the pH of the formulations are dominated by the the basic stabilizer, i.e. the alkali or alkaline-earth metal carbonate.

- 5 The ACE inhibitor compound is generally selected from enalapril, delapril, lisinopril, moexipril, perindopril, quinapril, ramipril,trandolapril, and pharmaceutically acceptable salts thereof. In particular, stable formulations of quinapril or a salt thereof are suitably manufactured according to the invention disclosed herein.
- 10 In yet further useful embodiments, the formulation of of the present invention further comprises in the range of about 0.5 – 50 wt% of a pharmaceutically active compound selected from the group containing diuretics including hydrochlorothiazide; antitussives including dextromethorphan, dextromethorphan hydrobromide, noscapine, carbetapentane citrate, and chlophedianol hydrochloride; antihistamines
- 15 including chloepheniramine maleate, phenindamine tartrate, pyrilamine maleate, doxylamine succinate, and phenyltoloxamine citrate; decongestants including phenylephedrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride, ephedrine; and alkaloids such as codeine phosphate, codeine sulfate, and morphine. The suitable amount of a further
- 20 pharmaceutically active compound such as the above listed depends on the particular compound depende on the activity of the compound and its suitable dose, and the dose weight of the pharmaceutical formulation.

EXAMPLES

Example 1

- 5 The following materials were combined by the wet granulation method for the manufacture of 5 mg quinapril tablets.

	Quinapril hydrochloride	5.4	mg
	Magnesium carbonate	63	mg
10	Calcium hydrogen phosphate anhydrous	46.4	mg
	Starch pregelatinized	21	mg
	Croscarmellose sodium	2.8	mg
	Magnesium stearate	1.4	mg

15

Example 2

- The following materials were processed by wet granulation for 10/12.5 mg tablets with Quinapril and Hydrochlorothiazide.

	Quinapril hydrochloride	10.8	mg
	Hydrochlorothiazide	12.5	mg
25	Magnesium carbonate	49	mg
	Calcium hydrogen phosphate anhydrous	42.5	mg
	Starch pregelatinized	21	mg
	Croscarmellose sodium	2.8	mg
30	Magnesium stearate	1.4	mg

Example 3


- 35 Stability of the tablets prepared in the Examples 1-2 were tested at 40°C for 9 days.

Degradation products (%)			
	<u>Quinapril DKP</u>	<u>Quinaprilat</u>	
40	Example 1	0.2	1.2
	Example 2	0.3	0.6
45	(DKP = diketopiperazine)		


CLAIMS

1. A pharmaceutical formulation comprising:

a. 0.5 – 50 wt% of a compound of formula I;



wherein R¹ is hydrogen or alkyl having one to five carbon atoms; R² is hydrogen or C₁-C₄ alkyl or the group



in which A and B independently denote hydrogen or C₁-C₄ alkyl and n is 1-4; R³ and R⁴ together with the atoms they are connected to form a heterocyclic, mono-, di-, or tricyclic ring system which is optionally substituted with C₁-C₄ alkoxy; R⁵ is methyl or phenyl; and pharmaceutically acceptable salts thereof;

b. 5 – 90 wt% of an alkali or alkaline earth metal carbonate;

c. 5 – 90 wt% of an insoluble alkaline-earth metal salt of hydrogen phosphate;

with the proviso that the formulation does not contain a substantial amount of a saccharide compound.

2. The formulation of claim 1, wherein the alkali or alkaline-earth metal carbonate is selected from magnesium carbonate, sodium hydrogen carbonate and sodium carbonate.

3. The formulation of claim 1, wherein the amount of the alkaline-earth metal carbonate is at least the equivalent of the amount of the active compound of formula I.

4. The formulation of claim 1, wherein the compound of formula I is selected from the group containing enalapril, delapril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, and pharmaceutically acceptable salts thereof.
5. The formulation of claim 1 wherein the formulation comprises in the range of about 1 – 15 wt% of the compound of formula 1.
6. The formulation of claim 1 wherein the formulation comprises in the range of about 25 – 75 wt% of the alkali or alkaline earth metal carbonate.
7. The formulation of claim 1 wherein the formulation comprises in the range of about 15 – 50 wt% of the salt of an insoluble alkaline earth metal hydrogen phosphate.
8. The formulation of any of the preceding claims wherein the compound of formula I is quinapril or a pharmaceutically acceptable salt thereof.
9. The formulation of claim 1 further comprising 0.5 – 50 wt% of a pharmaceutically active compound selected from the group containing diuretics including hydrochlorothiazide; antitussives including dextromethorphan, dextromethorphan hydrobromide, noscapine, carbetapentane citrate, and chlophedianol hydrochloride; antihistamines including chlopheniramine maleate, phenindamine tartrate, pyrilamine maleate, doxylamine succinate, and phenyltoloxamine citrate; decongestants including phenylephedrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride, ephedrine; and alkaloids such as codeine phosphate, codeine sulfate, and morphine.

ABSTRACT

Stable formulations of ACE-inhibitor compounds such as quinapril can be produced with the use of basic compounds as stabilizers, preferably alkali- or alkaline earth metal carbonates, wherein an insoluble alkaline-earth metal hydrogen phosphate is used as a preferred filler substance.